PRKACA antibody (Lys82, N-Term)
Quick Overview for PRKACA antibody (Lys82, N-Term) (ABIN2340987)
Target
See all PRKACA AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- Lys82, N-Term
-
Cross-Reactivity
- Human
-
Cross-Reactivity (Details)
- Calculated cross reactivity: Hu
-
Characteristics
- PRKACA, NT (K82) (cAMP-dependent Protein Kinase Catalytic Subunit alpha, PKA C-alpha, PKACA)
-
Purification
- Purified by ammonium sulfate precipitation.
-
Immunogen
- Synthetic peptide selected from the N-terminal(K282) region of human PRKACA (KLH).
-
Isotype
- IgG
-
-
-
-
Application Notes
- Optimal working conditions should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- Supplied as a liquid in PBS, 0.84 % sodium azide.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- -20°C
-
-
- PRKACA (Protein Kinase A, alpha (PRKACA))
-
Alternative Name
- PRKACA
-
NCBI Accession
- NP_002721
-
UniProt
- P17612
-
Pathways
- NF-kappaB Signaling, Hedgehog Signaling, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Thyroid Hormone Synthesis, Carbohydrate Homeostasis, Myometrial Relaxation and Contraction, M Phase, G-protein mediated Events, Signaling Events mediated by VEGFR1 and VEGFR2, Interaction of EGFR with phospholipase C-gamma, Thromboxane A2 Receptor Signaling, VEGFR1 Specific Signals, Lipid Metabolism, SARS-CoV-2 Protein Interactome, The Global Phosphorylation Landscape of SARS-CoV-2 Infection
Target
-